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Abstract
The coronavirus disease 19 (COVID-19) pandemic is currently the most acute healthcare challenge in the world. Despite 
growing knowledge of the nature of Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2), treatment options 
are still poorly defined. The safety of non-steroidal anti-inflammatory drugs (NSAIDs), specifically ibuprofen, has been 
openly questioned without any supporting evidence or clarity over dose, duration, or temporality of administration. This 
has been further conflicted by the initiation of studies to assess the efficacy of ibuprofen in improving outcomes in severe 
COVID-19 patients. To clarify the scientific reality, a literature search was conducted alongside considerations of the phar-
macological properties of ibuprofen in order to construct this narrative review. The literature suggests that double-blind, 
placebo-controlled study results must be reported and carefully analysed for safety and efficacy in patients with COVID-19 
before any recommendations can be made regarding the use of ibuprofen in such patients. Limited studies have suggested: 
(i) no direct interactions between ibuprofen and SARS-CoV-2 and (ii) there is no evidence to suggest ibuprofen affects the 
regulation of angiotensin-converting-enzyme 2 (ACE2), the receptor for COVID-19, in human studies. Furthermore, in vitro 
studies suggest ibuprofen may facilitate cleavage of ACE2 from the membrane, preventing membrane-dependent viral entry 
into the cell, the clinical significance of which is uncertain. Additionally, in vitro evidence suggests that inhibition of the 
transcription factor nuclear factor-κB (NF-kB) by ibuprofen may have a role in reducing excess inflammation or cytokine 
release in COVID-19 patients. Finally, there is no evidence that ibuprofen will aggravate or increase the chance of infection 
of COVID-19.
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Introduction
The world is currently impacted by the pandemic spread 
of Coronavirus-disease-2019 (COVID-19) caused by the 
Severe Acute Respiratory Syndrome coronavirus-2 (SARS-
CoV-2). Efforts to overcome the morbidity and mortality 
caused by this novel virus have been hampered by a lack 
of knowledge of the SARS-CoV-2 virus, particularly with 
regard to virulence, individual risk factors to host responses 
and appropriate treatment (Rokni et al. 2020). It is becoming 
clear that the increased incidence of life-threatening cases 
caused by SARS-CoV-2 are, at least in part, a consequence 
of a cytokine storm in some individuals. It is hypothesised 
that imbalances within the renin–angiotensin–aldoster-
one system (RAAS) and angiotensin-converting enzyme 2 
(ACE2) play a role in facilitating host cell infection (Hoff-
mann et al. 2020) or the inflammatory responses triggered 
by the SARS-CoV-2 virus (Liu et al. 2020a).
Concerns regarding the use of ibuprofen originated after 
the French Health Ministry issued advice on the 14th March 
2020 to avoid using non-steroidal anti-inflammatory drugs 
(NSAIDs) to treat symptoms of COVID-19 (Day 2020). 
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This triggered a debate within social and mainstream media 
as well as the scientific community, further propagated by 
the suggestion that ibuprofen could upregulate ACE2 (Fang 
et al. 2020b). Global shortages of paracetamol that occurred 
during the pandemic (Newton et al. 2020) compounded the 
issue, leaving patients with limited choice for symptomatic 
relief treatments in the face of mixed safety messages and 
little or no symptomatic treatment options for individuals for 
whom paracetamol was contraindicated.
Clinical judgement should be based on balanced scien-
tific opinion and the principles of evidence-based medicine 
(Akobeng 2005). The generation and analysis of evidence is 
essential to provide treatment recommendations, influence 
healthcare professionals’ opinions and inform patient’s self-
care decisions during times of crisis. Public questioning of 
the safety of a drug with a lack of substantiation or clarity 
over the dose, duration, chronicity, or class effect, renders 
making informed safety recommendations impossible. This 
shifts the responsibility of decision-making to practitioners, 
and ultimately to an excessively cautious approach in the 
face of significant uncertainty.
This article provides a safety and efficacy assessment of 
the pharmacological actions of ibuprofen and reviews the 
literature associated with ibuprofen’s potential benefits and 
risks in relation to SARS-CoV-2 infection.
RAAS and its role in inflammation
The renin–angiotensin–aldosterone system (RAAS) is 
a complex system of enzymes, vasoactive peptides, and 
hormones which controls numerous functions in multiple 
organs. The role of the RAAS expands beyond the homeo-
static regulation of blood pressure, electrolyte excretion, and 
fluid balance (Muñoz-Durango et al. 2016) and is now also 
considered to play an important role in the regulation of 
inflammation (Parajuli et al. 2014). The control mechanisms 
involved in the homeostatic regulation of inflammatory sig-
nalling pathways within the RAAS are shown in Fig. 1. The 
ACE2 axis forms a counter-regulatory pathway, opposing 
the pro-inflammatory ACE axis and its downstream effectors 
such as the inflammatory cytokine tumour necrosis factor 
alpha (TNFα) (Simoes e Silva et al. 2013).
Disruption to the homeostatic control mechanisms regu-
lating these inflammatory pathways can contribute to the 
pathogenesis of disease such as cardiac hypertrophy, pul-
monary hypertension, glomerulonephritis, lung injury, 
sepsis, and acute pancreatitis (Tikellis and Thomas 2012; 
Zisman 2005). Imbalances within the RAAS (such as an 
increased ACE:ACE2 ratio) favouring an increase in the 
active peptide angiotensin II (Ang II), result in amplifica-
tion of the angiotensin II type I receptor  (AT1R) expression 
and activity (Elton and Martin 2007). This includes surges 
of downstream inflammatory mediators, such as NF-κB, 
cyclooxygenase 2 (COX2), and mitogen-activated protein 
kinase (MAPK); as well as cytokine production such as 
interleukin-6 (IL-6), TNFα, and transforming growth fac-
tor beta 1 (TGF-β1) (Suzuki et al. 2003). The deleterious 
inflammatory effects of homeostatic failure of the RAAS 
pathway are highlighted in ACE2-knockout mice, where 
increases of reactive oxygen species (ROS), inflamma-
tory cytokines, and enhanced oxidative stress are observed 
(Alghamri et al. 2013).
The study of patients with chronic complex immune-
mediated diseases, such as rheumatoid arthritis and lupus, 
helps to extrapolate these findings to humans. The observa-
tion of increased activity of ACE in pleural fluid, increased 
adverse cardiovascular outcomes (mediated by vascular 
inflammation), and reversibility with the administration of 
ACE inhibitors (ACEis) or angiotensin receptor blockers 
demonstrate that an imbalance of the RAAS does exist in 
cases of chronic inflammation (Teplitsky et al. 2006; Zis-
man 2005).
Angiotensin‑converting enzyme 2
ACE2 has been identified as a binding site for the SARS-
CoV-2 spike protein, which contains two distinct functional 
domains, termed S1 and S2, both of which are necessary for 
viral entry into a host cell (Fig. 2) (Hoffmann et al. 2020). 
ACE2 is a homologue of ACE and a key enzyme involved 
in the synthesis of bioactive components of the RAAS. It 
is a type 1 transmembrane protein (N-terminus extracel-
lular, C-terminus intracellular) and it acts as a pleiotropic 
mono-carboxypeptidase responsible for production of angio-
tensin(1–7) via hydrolysing Ang II (Douglas et al. 2004). 
Despite the similarity, ACE2 differs from ACE both in its 
lack of inhibition by ACEis and substrate specificity (Dono-
ghue et al. 2000).
The majority (approximately 83%) of ACE2-expressing 
cells are alveolar epithelial type II cells (AECII) (Zou et al. 
2020) suggesting that SARS-CoV-2 has a high affinity for 
lung tissue and subsequent infection, although it is also 
expressed in many extrapulmonary tissues including heart, 
kidney, endothelium, and the small intestine (Crackower 
et al. 2002; Danilczyk et al. 2006; Hamming et al. 2004). 
Several factors are known to repress ACE2 activation, such 
as the presence of pro-inflammatory cytokines (Chen et al. 
2020a), the action of aldosterone via a NADPH oxidase 
pathway (Keidar et al. 2005), and stimulation of  AT1R (Igase 
et al. 2005).
ACE2 contains only a single active domain (N domain) 
rather than the two catalytic domains (N and C domains) of 
ACE (Towler et al. 2004). This is of significance when it is 
considered that ACE2 can be cleaved from the membrane of 
cells in which it is expressed (Epelman et al. 2008), mediated 
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by the protease ADAM-17, which causes its release into a 
soluble form with a catalytically active soluble N ectodo-
main that circulates in the extracellular environment (Lam-
bert et al. 2005). In normal health status, circulating ACE2 
levels are low compared with membrane-bound levels (Rice 
et al. 2006). Interestingly, given that the circulating form 
of ACE2 lacks the membrane anchor used as the cell entry 
point for SARS-CoV-2, it has been presented as a potential 
therapeutic target for prevention of infection of the virus, via 
acting as a decoy for the viral S-protein required for entry 
into its host’s cells (Batlle et al. 2020).
Generally speaking, ACE2 expression is low in good 
health, but levels are seen to rise in a number of pathologies 
(Lew et al. 2008) which incidentally are most grossly asso-
ciated with more severe courses of infection. For example, 
disorders such as diabetes, hypertension and cardiovascular 
disease are associated with imbalances in the RAAS (Zem-
lin and Wiese 2020); changes to expression levels are sug-
gested to be compensatory rather than causal as the system 
shifts the balance in order to rescue damage and restore 
homeostasis. It is worth noting that variation exists in its 
expression and regulation, depending on the organ and tis-
sue type in question. Genetic variants in the gene encod-
ing ACE2 have the potential to affect ACE2 levels in the 
human body: the Leeds Family Study, a well-characterised 
population of 89 healthy probands and their first-, second-, 
Fig. 1  The balancing role of 
angiotensin-converting enzyme 
2 (ACE2) in the renin–angio-
tensin–aldosterone system 
(RAAS). In a situation where 
ACE2 is downregulated, AngII 
levels rise and its concomitant 
binding on  AT1R increases sys-
temic inflammation via produc-
tion of inflammatory mediators. 
Ang angiotensin, NEP neprily-
sin, ACE angiotensin-converting 
enzyme, AT1R angiotensin type 
1 receptor, AT2R angiotensin 
type 2 receptor, MasR Mas 
receptor
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or third-degree relatives, elucidated that up to 67% of the 
phenotypic variation in circulating ACE2 levels could be 
accounted for by genetic factors, ascertained by measur-
ing ACE, ACE2, and neutral endopeptidase (NEP) activi-
ties in plasma (Rice et al. 2006). The coding for ACE2 is 
located on the X-chromosome (Komatsu et al. 2002), which 
is hypothesised to afford greater protection to females than 
males in situations of severe illness, such as acute respira-
tory distress syndrome (ARDS) (Garami 2020), via ‘double 
dose’ gene effects. ARDS is a further clinical manifestation 
of severe viral infection.
RAAS, ACE2 and COVID‑19
ACE2 is not the only factor necessary for viral entry into the 
cell. As previously described, the spike (S) protein of SARS-
CoV-2 contains two distinct functional domains, S1 and 
S2, of which both are necessary for viral entry into a host 
cell. S1 is responsible for the first stages of viral entry and 
contains the receptor-binding domain. S2 acts in the later-
stage fusion of the cell and viral membranes and contains 
amino acid sequences necessary for continuing infiltration. 
For fusion to take place, the S-protein is cleaved by cellu-
lar proteases; this step is critical, as it allows for the fusion 
sequences to be exposed (Belouzard et al. 2009; Walls et al. 
2020).
Such cleavage of membrane-bound ACE2 is thought to be 
facilitated by transmembrane protease serine 2 (TMPRSS2), 
which has been demonstrated to be essential for early entry 
and viral spread of SARS-CoV-2, through splitting the spike 
protein and establishing further penetration changes (Fig. 2) 
(Iwata-Yoshikawa et al. 2019). An Italian cohort study found 
no significant evidence that ACE2 is associated with disease 
severity/sex bias in the Italian population; rather, their analy-
sis suggested a role for TMPRSS2 variants and expression 
levels in modulating SARS-CoV-2 severity (Asselta et al. 
2020).
SARS-CoV-2 is capable of downregulating the levels of 
ACE2 receptors upon the surface of infected cells (Zhang 
et al. 2020a). Binding to ACE2 stimulates clathrin-depend-
ent endocytosis of both the virus and the receptor; further-
more, binding of the spike protein also induces ADAM-17 
Fig. 2  a The entry of severe acute respiratory syndrome coronavi-
rus-2 (SARS-CoV-2) into cells is mediated by the binding of the viral 
spike (S) glycoprotein to membrane-bound angiotensin-converting 
enzyme 2 (ACE2). ACE2 levels on the plasma membrane are regu-
lated by the metalloproteinase ADAM-17, which promotes shedding 
of ACE2 with its active N domain into the circulation. The cleaved 
portion of ACE2, which does not contain the membrane-bound 
domain necessary for viral entry into the cell, may act as a decoy 
for the viral spike proteins. It is hypothesised that ibuprofen may be 
able to activate ADAM-17 and thus prevent membrane-bound ACE2-
dependent infection of the cell. b The enzyme transmembrane pro-
tein, serine 2 (encoded for by the TMPRSS2 gene) is necessary for 
the proteolytic cut at the S1/S2 site on the viral S glycoprotein for 
uptake into the cell and viral replication. It is hypothesised that ibu-
profen may be able to downregulate expression of the enzyme, and 
thus prevent TMPRSS2-dependent viral entry into the cell
A narrative review of the potential pharmacological influence and safety of ibuprofen on…
1 3
activity, in turn reducing the amount of ACE2 expressed on 
the cell surface (Clarke and Turner 2012). There are two 
likely implications of a downregulation of ACE2: (1) that 
circulating levels of Ang II will increase in the absence of 
an enzyme capable of cleaving it; (2) protective levels of 
Ang(1–7) will decrease, reducing its conferred protective 
and anti-inflammatory effects and tipping the balance in 
favour an inflammatory state.
Given the observation that system-wide imbalances 
in the ACE:ACE2 ratio favouring the pro-inflammatory 
ACE axis are commonly observed in certain disease 
states commonly comorbid in severe COVID-19, it could 
be hypothesised that immune dysregulation of the RAAS 
and associated increases in pro-inflammatory mediators in 
the lungs may play a central role in the pathophysiology of 
SARS-CoV-2, such as induction of acute lung injury (ALI) 
or ARDS—both of which are notable causes of death in 
critically ill patients suffering from COVID-19 (Wu et al. 
2020). This is supported by the fact that SARS-CoV-2 
infection further exacerbates the imbalance, by downreg-
ulating ACE2 upon infection (Zhang et al. 2020a). Fur-
thermore, age is an independent risk factor for mortality 
in patients admitted with COVID-19 (Ruan et al. 2020), 
potentially correlating with the observation that ACE2 
expression reduces with age in rats (Xie et al. 2006). The 
data also suggest a disproportionate rate of disease occur-
rence, severity, and worse outcomes in males compared to 
females during this pandemic (Jin et al. 2020). These asso-
ciations might be interpreted to indicate that low ACE2 
during times of health is appropriate, but the ability to 
regulate overactive RAAS or the RAAS–SCoV axis dur-
ing illness is, at least in part, dependent on ACE2. For 
instance, one study identified a higher expression of the 
lung-protective  AT2 receptor among women, which could 
explain the disproportionately lower mortality in female 
COVID-19 subjects (Hilliard et al. 2012). Furthermore, as 
previously discussed, women and children are seen to have 
elevated levels of circulating ACE2 in comparison to men 
and the elderly (Ciaglia et al. 2020).
An upregulation of ACE2 has been suggested to offer 
pulmono-protective effects against the lung damage trig-
gered by the virus, by reducing Ang II binding on  AT1R 
and thus reducing production of downstream damaging 
effectors such as TGF-β1 (Kuba et al. 2005). Therefore, it is 
not fully understood whether higher levels of ACE2 might 
paradoxically confer increased protection against damage 
mediated by the virus. It is worth noting that intraperitoneal 
injections of recombinant human ACE2 protein at a dose 
of 0.1 mg kg−1 into mice has conferred protection against 
severe ALI, as measured by percentage change in lung 
elastance induced by acid aspiration (which mimics human 
ALI/ARDS, frequently caused by aspiration of gastric con-
tents) (Imai et al. 2005).
Such protective functions of ACE2 in the body may also 
help to explain why patients with existing comorbidities 
(such as diabetes, hypertension and cardiovascular disease) 
are most grossly associated with more severe courses of 
infection with SARS-CoV-2. When it is considered that indi-
viduals with these comorbidities have a lower level of ACE2 
at baseline compared to their healthy counterparts, infection 
further exacerbates this imbalance in ACE2 compared to 
ACE, leading to a heightened predisposition to inflamma-
tory damage (Fig. 3) (Oudit et al. 2009). Although small 
and with limited capacity for repeat, a cohort study of 12 
SARS-CoV-2 patients demonstrated that circulating Ang II 
levels were markedly elevated compared to healthy controls, 
which was linearly correlated with viral load (P = 0.035) 
(Liu et al. 2020b), indicating that such downregulation of 
ACE2 could facilitate the multi-organ damage associated 
with viral infection.
Fig. 3  Balance in favour of the ACE–Ang II–AT1R axis over the 
ACE2–Ang(1–7)–Mas axis in the development of or injury in certain 
disease states. Infection with severe acute respiratory coronavirus 2 
(SARS-CoV-2) only serves to further reduce levels of angiotensin-
converting enzyme 2 (ACE2), pushing the balance further in the 
direction of injury for those with certain comorbidities. CV indicates 
cardiovascular disease
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RAAS, COVID‑19 and ibuprofen
RAAS plays a particularly important role in the course of 
SARS-CoV-2 infection. This interaction appears to be multi-
factorial, through facilitation of viral entry into the host cell 
and modulation of the inflammatory response observed in 
reaction to the virus. Equally, ibuprofen has multiple modes 
of action that underpin its pharmacology, which are depend-
ent on its pharmacokinetics.
Antiviral properties
Ibuprofen is administered as a racemic mixture: the R(−)-
enantiomer undergoes extensive interconversion to the S(+)-
enantiomer in vivo. The S(+)-enantiomer is considered to 
be the more pharmacologically active enantiomer and is 
capable of inhibiting cyclooxygenase (COX), a key enzyme 
responsible for inflammation and pain, at clinically relevant 
concentrations. On reviewing the literature, no studies were 
found to indicate that either the R(−) or S(+)‐enantiom-
ers would structurally interact with the virus, specifically 
the spike proteins, which are essential to anchor the virus 
to the cells surface. Again, no studies were found within 
the literature to demonstrate that either enantiomer would 
directly interact with either receptors present on ACE2 or 
TMPRSS2 providing competition or affecting affinity of the 
SARS-CoV-2 virions.
Ibuprofen is not considered to be an antiviral agent, how-
ever a potential indirect relationship between ibuprofen and 
ACE2 is described in vivo using streptozotocin-induced dia-
betic rats which were fed ibuprofen (40 mg/kg—with allo-
metric scaling, human equivalent dose equates to 450 mg 
for a 70 kg person) once daily by gavage for 8 weeks (Qiao 
et al. 2015). The results were evaluated by assessment of 
cardiac fibrosis and evaluation of TGF-β1 and the mamma-
lian target of rapamycin (mTOR), both major components 
of the RAAS. This was a small study; however, a beneficial 
outcome of ibuprofen, which ameliorated the development 
of cardiac fibrosis in the diabetic group, was observed—an 
effect that was hypothesised to be the result of normalisa-
tion of the ACE:ACE2 ratio in the diabetic mice. The mode 
of enhancement of the ACE2/Ang(1–7)/MasR axis by ibu-
profen likely occurred via its direct inhibitory effects on 
the downstream pro-inflammatory mediators (e.g. NF-kB, 
COX2 & TGF-β1) of the ACE/Ang II/AT1R axis. In sup-
port of this, the study also suggests that the normalisation 
of the ACE:ACE2 ratio is likely to be an indirect pharma-
codynamic effect: a consequence of the restoration of the 
inflammatory imbalance caused by diabetic dysregulation of 
the RAAS in favour of ACE and a pro-inflammatory state. 
However, no effect was seen in the control group which did 
not have induced diabetes. In the context of COVID-19, 
extrapolation of this result into healthy humans should be 
undertaken with caution, given the dosage regime in the 
study (40 mg/kg daily for 8 weeks) is not comparable to a 
standard maximum daily OTC dose of 1200 mg of ibuprofen.
It could be hypothesised that ibuprofen may also indi-
rectly impact the cleavage of ACE2 from the cell membrane, 
thus limiting viral infectivity, given that the circulating form 
of ACE2 lacks the membrane anchor used as the cell entry 
point for SARS-CoV-2. The suggested mechanism mediating 
such effect is that ibuprofen’s insertion into the lipid bilayer 
of the cell membrane (Rojas-Valencia et al. 2018) facili-
tates activation of the NADPH oxidase complex and thus 
the release of superoxide anions into the extracellular milieu, 
which in turn generate an oxidative attack on the prodo-
main thiol groups (which mask the active site of ADAM-17), 
causing their removal (Diaz-Gonzalez and Sanchez-Madrid 
2015) and thus activation to process ACE2 cleavage. Given 
the lack of evidence of a direct pharmacodynamic interac-
tion with ACE2 or its mediators, it is not understood that 
ibuprofen leads to an overexpression of ACE2 and thus viral 
entry, as has been implied (Fang et al. 2020b). It is more fea-
sible to suggest that ibuprofen provides either no benefit or 
a possible protective effect, either through the attenuation of 
the enhanced inflammatory states observed in disease states 
identified to have worse outcomes in COVID-19, or through 
cleavage of membrane ACE2 to soluble ACE2, which is 
being considered as a plausible therapeutic opportunity 
(Batlle et al. 2020).
Furthermore, ibuprofen could impact viral entry via indi-
rect interaction with TMPRSS2. TMPRSS2 is androgen-
regulated (Lin et al. 1999); a randomised double-blinded 
placebo-controlled trial with an intervention of ibuprofen 
taken at a dose of 1200 mg daily for 6 weeks demonstrated 
that ibuprofen reduced the production of the androgen testos-
terone in a dose-dependent manner, likely through transcrip-
tional repression (Kristensen et al. 2018). In vitro studies 
support this mechanism through the inhibition of testoster-
one glucuronidation in human liver microsomes via inhibi-
tion of the enzymes that facilitate the process (such as the 
UDP-glucuronosyltransferase, UGT2B15) (Sten et al. 2009). 
The relevance of this evidence in the context of COVID-19 
infection is unclear. It could be hypothesised that ibuprofen 
could present a benefit in males through downregulation of 
TMPRSS2 via induced hypogonadism, however the extent of 
downregulation is still largely unknown. Any benefit would 
also need to be weighed up against any adverse effects of 
inducing a compensated hypogonadism and the relevance 
of acute symptomatic OTC dosing, given that a minimum of 
14 days would be needed to see any potential effects.
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Modulation of the immune response
Like other respiratory viruses (Ramos and Fernandez-
Sesma 2015), SARS-CoV-2 infection triggers a local 
immune response, recruiting macrophages and monocytes 
that respond to the infection, release cytokines, and prime 
adaptive T and B cell immune responses. In most cases, this 
response capably resolves the infection and clears the virus. 
However, in other cases, a dysfunctional immune response 
occurs which can cause severe lung and/or systemic injury. 
This is highlighted by the finding that in the blood of patients 
infected with SARS-CoV-2, there was a marked increase 
in interleukin 1β (IL-1β), interferon γ (IFN-γ), interferon-
inducible protein 10 (IP-10), and monocyte chemoattractant 
protein 1 (MCP-1), as well as IL-4 and IL-10 when com-
pared to that of SARS patients (Zhang et al. 2020b). It has 
therefore been hypothesised that excessive inflammation 
and an active cytokine storm contribute significantly to the 
pathogenesis of COVID-19.
The transcription factor NF-kB controls the expression of 
genes such as COX2, amongst a whole host of other down-
stream inflammatory mediators, and has multiple implica-
tions in the pathogenesis of SARS-CoV-2 infection. Firstly, 
NF-kB inhibition is seen to prevent upregulation of  AT1R 
in Zucker diabetic fatty rats (Luo et al. 2015), indicating 
its capability to promote expression of the  AT1R receptor 
and thus downstream inflammatory mediators. Secondly, 
NF-kB is witnessed to be utilised by the SARS-CoV virus 
to upregulate miRNA-200c-3p, which is capable of down-
regulating ACE2 via binding the 3′-untranslated region of 
ACE2 (Liu et al. 2017).
NSAIDs, and thus ibuprofen, are known to inhibit NF-kB 
activity during inflammatory responses: both the R(−)‐enan-
tiomer and the S(+)‐enantiomer inhibited the activation 
of NF‐κB in response to stimulation by prostaglandin  E2 
 (PGE2), a key mediator of inflammation, in Human Jurkat 
T‐lymphocytes (Scheuren et al. 1998). Normalising the 
levels of NF-kB may allow for the prevention of upregula-
tion of  AT1R and downregulation of ACE2 when it is over-
expressed in the presence of inflammation or viral infection. 
However, the clinical meaningfulness of the known effects 
of ibuprofen on cytokines (be it pro- or anti-inflammatory) 
are currently unknown in COVID-19 patients: the dose, 
timings of dose, severity of condition and the state of an 
individual’s immune response are all potential determining 
factors and should be thoroughly assessed before conclu-
sions can be drawn.
Interleukin-6 (IL-6), downstream of NF-kB, is over-
produced in COVID-19 patients (Chen et al. 2020b). Inter-
estingly, IL-6 leads to a relevant increase in cathepsin L, 
a lysosomal endopeptidase enzyme that can contribute to 
the internalisation and activation of SARS-CoV-2 (Abassi 
et al. 2020). Consequently, there are clinical trials involving 
anti-IL-6 therapies for the treatment of COVID-19 that are 
actively recruiting. Ibuprofen has been found to reduce IL-6 
in human synovial fluid (Gallelli et al. 2013) and in sputum 
(Chmiel et al. 2015); therefore, it will be important to report 
the use of ibuprofen (amongst other NSAIDs) in clinical 
studies of COVID-19 in order to better understand what 
impact it may have on cytokine production.
Administration of anti-inflammatory molecules provides 
therapeutic opportunities to modulate such a response. 
The anti-inflammatory actions of ibuprofen are well estab-
lished and in properly selected patients may be a reasonable 
approach to help reduce inflammatory damage related to the 
“cytokine storm”. For example, ibuprofen is documented 
to variously affect the production of the pro-inflammatory 
cytokines (IL‐1β, TNFα), as well as some intracellular sig-
nalling pathways in inflammatory cells (Rainsford 2015).
In this capacity, it is plausible that anti-inflammatory 
therapies that reduce NF‐κB levels, such as non-acetylated 
salicylates (salsalate), as well as ibuprofen may be able to 
prevent the damage caused by unabated cytokine storms 
and hyperinflammatory states associated with COVID-19 
(Fig. 4).
Discussion
In response to the current SARS-CoV-2 outbreak, the col-
lective, rapid output of research and literature around the 
world has been unprecedented, as scientists and academics 
attempt to understand the virus as the pandemic spreads. 
There has also been a proliferation in the availability of 
open-access journals or pre-print articles with little or 
no peer-review processes, which may lend themselves to 
become an important source of sensationalised news. The 
intent of this review article was to consider the salient 
and clinically relevant information within the literature in 
order to further understand the risk:benefit profile of the 
administration of OTC doses of ibuprofen in the context 
of COVID-19.
The literature contains strong evidence for the role of 
the RAAS, and in particular ACE2, in facilitating host 
cell infection, its downregulation thereof, and the conse-
quential immune response triggered by the SARS-CoV-2 
virus. We found no evidence in the literature to suggest a 
direct interaction between ibuprofen and ACE2 in humans. 
What is becoming increasingly clear is that severe and 
life-threatening cases of COVID-19 are, at least in part, 
a consequence of an excessive inflammatory response 
known as a “cytokine storm”. The specific components 
and triggers of the immune response in these patients are 
still not yet fully understood, but it is thought that such 
inflammatory mediators triggered by the virus may aber-
rantly destroy healthy cells (Tay et al. 2020). In addition 
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to the interaction between SARS-CoV-2 and ACE2 in host 
cell infection, the literature also provides biological plau-
sibility into how the RAAS could modulate the observed 
inflammatory response, recognising its physiological role 
as a key regulatory system of inflammation. The anti-
inflammatory actions of ACE2 may also explain some of 
the independent risk factors identified in emerging obser-
vational data, such as age (declining ACE2 and an ageing 
immune system) (Xie et al. 2006) and comorbidities such 
as diabetes and cardiovascular disease (associated with a 
dysregulation of the RAAS in favour of ACE) (McFarlane 
et al. 2003). Emerging knowledge of the anti-inflammatory 
nature of ACE2 and the downstream effects of Ang(1–7) 
binding to MasR has called into question the protective 
effects that increased levels of ACE2 might afford an 
individual infected with SARS-CoV-2. It is certain that as 
more observational and epidemiological data are generated 
globally from infected patients, an enhanced understand-
ing of the true situation surrounding ACE2 expression lev-
els in the susceptibility to, and severity of, SARS-CoV-2 
infection will be gained.
With fever and arthralgia being some of the most com-
mon symptoms displayed during the course of infection 
(Huang et al. 2020), the need for symptomatic relief and 
the ability to access appropriate self-medication is appre-
ciable. Ibuprofen, aspirin and paracetamol are amongst 
the most widely used analgesic–antipyretic medicines 
in the world. In terms of low-dose, short-duration use in 
otherwise healthy adults, ibuprofen is noted to be the least 
toxic of the three, demonstrated by the fact that it is rarely 
Fig. 4  Interaction of severe acute respiratory coronavirus 2 (SARS-
CoV-2) with the inflammatory system via downregulation of ACE2 
and potential therapeutic effects of ibuprofen in reducing inflamma-
tion. In the presence of the virus, ACE2 is downregulated, thus pre-
venting enzymatic hydrolysis of AngII into Ang(1–7). The result-
ing effect is there is increased production of the transcription factor 
NF-kB, which activates production of further inflammatory media-
tors. Ibuprofen has demonstrated ability to inhibit NF-kB, as well as 
other downstream inflammatory mediators such as interleukin-6, that 
seem to be upregulated upon viral infection. Furthermore, ibuprofen 
is hypothesised to activate ADAM-17 cleavage of ACE2 from the 
cell membrane, preventing viral entry into the cell. ACE = angioten-
sin-converting enzyme. Ang angiotensin, ATR1 type 1 angiotensin 
II receptor, AT2R type 2 angiotensin II receptor, COX2 cyclooxyge-
nase 2, ICAM intercellular adhesion molecule, IL interleukin, IFN 
interferon, JAK Janus kinase, MasR Mas receptor, NF-kB nuclear 
factor  kappa-light-chain-enhancer of activated B cells, SARS-CoV-2 
severe acute respiratory syndrome coronavirus 2, STAT3 signal trans-
ducer and activator of transcription 3, TGF transforming growth fac-
tor, TLR toll-like receptor, TNF tumour necrosis factor, TXA throm-
boxane, TYK tyrosine kinase, VEGF vascular endothelial growth 
factor
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associated with serious adverse events in low-risk patients 
(Derry et al. 2013; Rainsford 2012). This is attributable to 
the low dose–response curves for the anti‐inflammatory 
actions of ibuprofen, compared to the relatively high doses 
required for toxicity, thus giving this drug flexibility in its 
high therapeutic index, especially when compared with that 
of other NSAIDs and paracetamol (Rainsford 2012). The 
safety of ibuprofen use in SARS-CoV-2 infection has been 
questioned in a theoretical sense after demonstration of a 
potential to upregulate ACE2 expression in a singular animal 
model (Qiao et al. 2015). The foundation of this hypothesis 
is based on a single study in diabetic rats exposed to a daily 
dose of ibuprofen for 8 weeks (40 mg/kg, corresponding with 
450 mg dose for a 70 kg person). The increase in ACE2 
was shown in the heart only, and no distinction was made 
between membrane-bound ACE2 and soluble ACE2. The 
authors speculated that the ACE2 rise was due to inhibition 
of COX and/or activation of peroxisome proliferator-acti-
vated receptor γ without providing any evidence to support 
these claims. The citation of this finding in further literature 
(Fang et al. 2020b) postulated further unverified suggestions 
that increased expression of ACE2 would lead to enhanced 
susceptibility to viral infection and/or viral titres in cells, 
increasing the severity of the infection and leading to poorer 
prognoses. This review article provides a hypothesis on the 
underpinning mechanism which could explain the observed 
results or refute these positions.
Other speculative postulations against the use of NSAIDs, 
and ibuprofen in COVID-19, include suggestions that 
changes in the adaptive immune response caused by anti-
inflammatory, antipyretic agents may dampen natural host 
responses that are necessary to fight viral infection or even 
mask signs of infection (Fang et al. 2020a). However, no 
evidence was found to support that this may be the case 
or define the level of risk. Data emerging from China have 
demonstrated that in almost all cases of severe infection, 
high levels of IL-6 and many other pro-inflammatory 
cytokines (predominantly downstream of NF-kB) and TNFα 
were detected. Ibuprofen has multiple modes of action that 
underlie its anti-inflammatory effects including, but not lim-
ited, to the downregulation of inflammatory pathways such 
as NF-kB and inhibition of pro-inflammatory cytokines IL-6 
and TNFα. This suggests ibuprofen to be a safe and effective 
anti-inflammatory in the instance of SARS-CoV-2 infection 
in properly selected patients with low risk of NSAID-related 
complications. Further studies are warranted to establish 
the efficacy and mechanism of the control of inflamma-
tion in COVID-19 patients and associations with ACE2, in 
the context of ibuprofen and other drugs which may have 
similar modes of action. Ideally, clinical data will be gener-
ated in the form of the current gold standard requirements: 
mechanistic understanding will be gleaned from randomised, 
controlled clinical trials, which are designed to mitigate the 
protopathic bias that frequently confounds observational 
studies. However, it is acknowledged that with current 
restraints imposed by the pandemic, this data will be dif-
ficult to generate.
Conclusion
This review explored the literature for any potential altera-
tion of the risk/benefit profile in relation to SARS-CoV-2 
infection. In conclusion, there are tenable arguments for both 
additional benefit and risk, however the evidence base is 
insufficient to allow clinically meaningful conclusions to be 
drawn. At this time, ibuprofen should continue to be used 
as normal, with no change in the warnings for practitioners 
and patients alike and according to the licensed indications 
and instructions for use, remaining in consideration as part 
of the symptomatic treatment options in COVID-19—advice 
supported by all international professional and regulatory 
bodies. This is further confirmed by the analysis of obser-
vational data acquired from patient registries of SARS-CoV-
2-positive patients in (i) Israel, which demonstrated that ibu-
profen use was not associated with worse clinical outcomes 
compared with paracetamol or no antipyretic (Rinott et al. 
2020); (ii) Michigan, US, which demonstrated that NSAID 
use prior to admission was not associated with renal failure 
or increased mortality (Imam et al. 2020); and (iii) individu-
als with rheumatic diseases who demonstrated that exposure 
to NSAIDs was not associated with increased risk of hospi-
talisation (Gianfrancesco et al. 2020).
There is no current evidence to suggest a mechanism by 
which ibuprofen exacerbates, aggravates, or increases the 
chance of infection with SARS-CoV-2.
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